Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Johnson and Johnson
Harvard Business School
Medtronic
Dow

Last Updated: January 31, 2023

ANJESO Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which patents cover Anjeso, and what generic alternatives are available?

Anjeso is a drug marketed by Baudax and is included in one NDA. There are eight patents protecting this drug.

This drug has forty-seven patent family members in thirteen countries.

The generic ingredient in ANJESO is meloxicam. There are twenty-two drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the meloxicam profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Anjeso

A generic version of ANJESO was approved as meloxicam by AVONDALE PHARMS on June 1st, 2004.

  Try it Free

US Patents and Regulatory Information for ANJESO

ANJESO is protected by seven US patents and one FDA Regulatory Exclusivity.

Patents protecting ANJESO

Nanoparticulate meloxicam formulations
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INTRAVENOUS INJECTION

Nanoparticulate meloxicam formulations
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INTRAVENOUS INJECTION


Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INTRAVENOUS INJECTION

Method of treating pain in elderly patients with mild renal impairment
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INTRAVENOUS INJECTION IN PATIENTS WITH MILD RENAL IMPAIRMENT

Reduction of flake-like aggregation in nanoparticulate active agent compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INJECTION

Nanoparticulate meloxicam formulations
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INTRAVENOUS INJECTION

Reduction of flake-like aggregation in nanoparticulate active agent compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

FDA Regulatory Exclusivity protecting ANJESO

NEW PRODUCT
Exclusivity Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Baudax ANJESO meloxicam SOLUTION;INTRAVENOUS 210583-001 Feb 20, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Baudax ANJESO meloxicam SOLUTION;INTRAVENOUS 210583-001 Feb 20, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Baudax ANJESO meloxicam SOLUTION;INTRAVENOUS 210583-001 Feb 20, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Baudax ANJESO meloxicam SOLUTION;INTRAVENOUS 210583-001 Feb 20, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Baudax ANJESO meloxicam SOLUTION;INTRAVENOUS 210583-001 Feb 20, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Baudax ANJESO meloxicam SOLUTION;INTRAVENOUS 210583-001 Feb 20, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for ANJESO

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Norbrook Laboratories (Ireland) Limited Loxicom meloxicam EMEA/V/C/000141
DogsAlleviation of inflammation and pain in both acute and chronic musculoskeletal disorders. To reduce postoperative pain and inflammation following orthopaedic and soft-tissue surgery.CatsAlleviation of inflammation and pain in chronic musculoskeletal disorders in cats. To reduce postoperative pain after ovariohysterectomy and minor soft-tissue surgery.CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle. For use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle. For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.PigsFor use in noninfectious locomotor disorders to reduce the symptoms of lameness and inflammation. For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.HorsesFor use in the alleviation of inflammation and relief of pain in both acute and chronic musculoskeletal disorders.For the relief of pain associated with equine colic.
Authorised yes no no 2009-02-10
Le Vet Beheer B.V.  Novaquin meloxicam EMEA/V/C/003866
Alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders in horses.
Authorised no no no 2015-09-08
Le Vet Beheer B.V Meloxidolor meloxicam EMEA/V/C/002590
DogsAlleviation of inflammation and pain in both acute and chronic musculoskeletal disorders.Reduction of postoperative pain and inflammation following orthopaedic and soft-tissue surgery.CatsReduction of postoperative pain after ovariohysterectomy and minor soft-tissue surgery.CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs.For use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.PigsFor use in noninfectious locomotor disorders to reduce the symptoms of lameness and inflammation.For the relief of postoperative pain associated with minor soft-tissue surgery such as castration.For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.HorsesFor use in the alleviation of inflammation and relief of pain in both acute and chronic musculoskeletal disorders.For the relief of pain associated with equine colic.
Authorised yes no no 2013-04-22
Boehringer Ingelheim Vetmedica GmbH Novem meloxicam EMEA/V/C/000086
Novem 5-mg/ml solution for injection for cattle and pigs:CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.For use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.For the relief of postoperative pain following dehorning in calves.PigsFor use in noninfectious locomotor disorders to reduce the symptoms of lameness and inflammation.For the relief of postoperative pain associated with minor soft-tissue surgery such as castration.Novem 20-mg/ml solution for injection for cattle and pigs:CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.For use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.For the relief of postoperative pain following dehorning in calves.PigsFor use in noninfectious locomotor disorders to reduce the symptoms of lameness and inflammation.For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.Novem 40 mg/ml solution for injection for cattle:For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.
Authorised no no no 2004-03-02
Boehringer Ingelheim Vetmedica GmbH Metacam meloxicam EMEA/V/C/000033
Cats:Alleviation of mild to moderate post-operative pain and inflammation following surgical procedures, e.g. orthopaedic and soft tissue surgery.Alleviation of pain and inflammation in acute and chronic musculo-skeletal disorders.Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery.Cattle:For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs.For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.For the relief of post-operative pain following dehorning in calves.For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.Dogs:Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders.Reduction of post-operative pain and inflammation following orthopaedic and soft tissue surgery.Horses:For use in the alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders.For the relief of pain associated with equine colic.Alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders.Pigs: For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation.For the relief of post-operative pain associated with minor soft tissue surgery such as castration.For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.Guinea pigs:Alleviation of mild to moderate post-operative pain associated with soft tissues surgery such as male castration.
Authorised no no no 1998-01-07
Chanelle Pharmaceuticals Manufacturing Limited Rheumocam meloxicam EMEA/V/C/000121
DogsAlleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in dogs. To reduce post-operative pain and inflammation following orthopaedic and soft tissue surgery.CatsReduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery.Alleviation of mild to moderate post-operative pain and inflammation following surgical procedures in cats, e.g. orthopaedic and soft tissue surgery.Alleviation of pain and inflammation in acute and chronic musculo-skeletal disorders in cats.CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs. For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle. For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.PigsFor use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation. For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy. For the relief of post operative pain associated with minor soft tissue such as castration.HorsesAlleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders in horses..For the relief of pain associated with equine colic.
Authorised yes no no 2008-01-10
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for ANJESO

See the table below for patents covering ANJESO around the world.

Country Patent Number Title Estimated Expiration
Japan 2022505572 術前および他の薬物との組み合わせでのメロキシカムの静脈内投与方法 See Plans and Pricing
Hungary E032426 See Plans and Pricing
World Intellectual Property Organization (WIPO) 2005002542 See Plans and Pricing
Denmark 3434261 See Plans and Pricing
Canada 2517679 FORMULATIONS DE MELOXICANE NANOPARTICULAIRES (NANOPARTICULATE MELOXICAM FORMULATIONS) See Plans and Pricing
Japan 2012528171 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
Baxter
Merck
AstraZeneca
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.